Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jul 26, 2014; 6(7): 555-561
Published online Jul 26, 2014. doi: 10.4330/wjc.v6.i7.555
Published online Jul 26, 2014. doi: 10.4330/wjc.v6.i7.555
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors
Serhan Kupeli, Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Çukurova University, 01330 Adana, Turkey
Author contributions: Kupeli S solely contributed to this paper.
Correspondence to: Serhan Kupeli, MD, MSc, Associate Professor of Pediatrics, Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Çukurova University, Rektörlüğü, 01330 Adana, Turkey. serhankupeli@cu.edu.tr
Telephone: +90-32-23387444 Fax: +90-32-23387444
Received: December 13, 2013
Revised: April 10, 2014
Accepted: May 14, 2014
Published online: July 26, 2014
Processing time: 249 Days and 23.6 Hours
Revised: April 10, 2014
Accepted: May 14, 2014
Published online: July 26, 2014
Processing time: 249 Days and 23.6 Hours
Core Tip
Core tip: With substantial increase in survival rates from cancer, late adverse effects of cancer therapy have become extremely important. Mediastinal radiotherapy and cardiotoxic chemotherapeutic agents are routinely used to treat Hodgkin lymphoma (HL) but are commonly associated with a variety of cardiovascular complications including coronary artery disease (CAD). For surviving individuals after HL treatment, coronary computed tomography angiography is a non-invasive and useful method in detecting CAD at an early stage. Survivors of HL especially treated with combined chemoradiotherapy at young ages, who carry the risk of CAD development are candidates for coronary computed tomography angiography.